Hepatitis C Virus
[Display omitted] Hepatitis C virus (HCV) is an enveloped, RNA virus transmitted through blood-to-blood contact. It infects humans only and primarily targets liver cells. HCV evades innate and adaptive immunity and establishes chronic infections in 70% of cases. If untreated, 20% of patients develop...
Gespeichert in:
| Veröffentlicht in: | Trends in microbiology (Regular ed.) 2019-04, Vol.27 (4), p.379-380 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 380 |
|---|---|
| container_issue | 4 |
| container_start_page | 379 |
| container_title | Trends in microbiology (Regular ed.) |
| container_volume | 27 |
| creator | Pietschmann, Thomas Brown, Richard J.P. |
| description | [Display omitted]
Hepatitis C virus (HCV) is an enveloped, RNA virus transmitted through blood-to-blood contact. It infects humans only and primarily targets liver cells. HCV evades innate and adaptive immunity and establishes chronic infections in 70% of cases. If untreated, 20% of patients develop liver cirrhosis, and a fraction of these progress to hepatocellular carcinoma. Annually, 400000 patients die globally due to HCV infection. Direct-acting antivirals (DAAs) are licensed and target three viral proteins: the NS3-4A protease needed for processing the viral polyprotein, the NS5A phosphoprotein that regulates RNA replication and virus assembly, and the viral RNA-dependent RNA polymerase (NS5B) that catalyzes genome replication. Combination therapies cure more than 95% of treated patients. Approximately 71 million people are chronically infected and 1.7 million new infections occur annually. Treatment-induced cure does not protect from viral reinfection. A prophylactic vaccine is under development.
[Display omitted] |
| doi_str_mv | 10.1016/j.tim.2019.01.001 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2179519321</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0966842X19300137</els_id><sourcerecordid>2209580579</sourcerecordid><originalsourceid>FETCH-LOGICAL-c424t-9e518bce2adae943798b32d1236a97805fe93f118d81bcf666e5b52e0c1aa2f83</originalsourceid><addsrcrecordid>eNp9kDFPwzAQhS0EoqUwMLKgSiwsCXdOnNhiQhVQpEosgNgsx7lIjtqm2AkS_x5XLQwMTLd8773Tx9gFQoqAxU2b9m6VckCVAqYAeMDGKEuZ5JmEQzYGVRSJzPn7iJ2E0AKAEFwcs1EGJagSyjE7n9PG9K53YTqbvjk_hFN21JhloLP9nbDXh_uX2TxZPD8-ze4Wic153ieKBMrKEje1IZVnpZJVxmvkWWFUKUE0pLIGUdYSK9sURUGiEpzAojG8kdmEXe96N777GCj0euWCpeXSrKkbguZYKoEq4xjRqz9o2w1-Hb_TnIMSca1UkcIdZX0XgqdGb7xbGf-lEfTWl2519KW3vjSgjr5i5nLfPFQrqn8TP4IicLsDKKr4dOR1sI7Wlmrnyfa67tw_9d94anej</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2209580579</pqid></control><display><type>article</type><title>Hepatitis C Virus</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Pietschmann, Thomas ; Brown, Richard J.P.</creator><creatorcontrib>Pietschmann, Thomas ; Brown, Richard J.P.</creatorcontrib><description>[Display omitted]
Hepatitis C virus (HCV) is an enveloped, RNA virus transmitted through blood-to-blood contact. It infects humans only and primarily targets liver cells. HCV evades innate and adaptive immunity and establishes chronic infections in 70% of cases. If untreated, 20% of patients develop liver cirrhosis, and a fraction of these progress to hepatocellular carcinoma. Annually, 400000 patients die globally due to HCV infection. Direct-acting antivirals (DAAs) are licensed and target three viral proteins: the NS3-4A protease needed for processing the viral polyprotein, the NS5A phosphoprotein that regulates RNA replication and virus assembly, and the viral RNA-dependent RNA polymerase (NS5B) that catalyzes genome replication. Combination therapies cure more than 95% of treated patients. Approximately 71 million people are chronically infected and 1.7 million new infections occur annually. Treatment-induced cure does not protect from viral reinfection. A prophylactic vaccine is under development.
[Display omitted]</description><identifier>ISSN: 0966-842X</identifier><identifier>EISSN: 1878-4380</identifier><identifier>DOI: 10.1016/j.tim.2019.01.001</identifier><identifier>PMID: 30709707</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Antiviral Agents - therapeutic use ; antiviral therapy ; Carcinoma, Hepatocellular - virology ; HCV ; Hepacivirus - drug effects ; Hepacivirus - physiology ; Hepatitis ; Hepatitis C ; Hepatitis C - drug therapy ; Hepatitis C - immunology ; Hepatitis C - prevention & control ; Hepatitis C - virology ; Humans ; Immune Evasion ; infection ; liver disease ; Serine Proteases ; Viral Nonstructural Proteins ; Viral Proteins - metabolism ; Viral Vaccines ; Virus Assembly ; Virus Replication ; Viruses</subject><ispartof>Trends in microbiology (Regular ed.), 2019-04, Vol.27 (4), p.379-380</ispartof><rights>2019 Elsevier Ltd</rights><rights>Copyright © 2019 Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Science Ltd. Apr 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c424t-9e518bce2adae943798b32d1236a97805fe93f118d81bcf666e5b52e0c1aa2f83</citedby><cites>FETCH-LOGICAL-c424t-9e518bce2adae943798b32d1236a97805fe93f118d81bcf666e5b52e0c1aa2f83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.tim.2019.01.001$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30709707$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pietschmann, Thomas</creatorcontrib><creatorcontrib>Brown, Richard J.P.</creatorcontrib><title>Hepatitis C Virus</title><title>Trends in microbiology (Regular ed.)</title><addtitle>Trends Microbiol</addtitle><description>[Display omitted]
Hepatitis C virus (HCV) is an enveloped, RNA virus transmitted through blood-to-blood contact. It infects humans only and primarily targets liver cells. HCV evades innate and adaptive immunity and establishes chronic infections in 70% of cases. If untreated, 20% of patients develop liver cirrhosis, and a fraction of these progress to hepatocellular carcinoma. Annually, 400000 patients die globally due to HCV infection. Direct-acting antivirals (DAAs) are licensed and target three viral proteins: the NS3-4A protease needed for processing the viral polyprotein, the NS5A phosphoprotein that regulates RNA replication and virus assembly, and the viral RNA-dependent RNA polymerase (NS5B) that catalyzes genome replication. Combination therapies cure more than 95% of treated patients. Approximately 71 million people are chronically infected and 1.7 million new infections occur annually. Treatment-induced cure does not protect from viral reinfection. A prophylactic vaccine is under development.
[Display omitted]</description><subject>Antiviral Agents - therapeutic use</subject><subject>antiviral therapy</subject><subject>Carcinoma, Hepatocellular - virology</subject><subject>HCV</subject><subject>Hepacivirus - drug effects</subject><subject>Hepacivirus - physiology</subject><subject>Hepatitis</subject><subject>Hepatitis C</subject><subject>Hepatitis C - drug therapy</subject><subject>Hepatitis C - immunology</subject><subject>Hepatitis C - prevention & control</subject><subject>Hepatitis C - virology</subject><subject>Humans</subject><subject>Immune Evasion</subject><subject>infection</subject><subject>liver disease</subject><subject>Serine Proteases</subject><subject>Viral Nonstructural Proteins</subject><subject>Viral Proteins - metabolism</subject><subject>Viral Vaccines</subject><subject>Virus Assembly</subject><subject>Virus Replication</subject><subject>Viruses</subject><issn>0966-842X</issn><issn>1878-4380</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kDFPwzAQhS0EoqUwMLKgSiwsCXdOnNhiQhVQpEosgNgsx7lIjtqm2AkS_x5XLQwMTLd8773Tx9gFQoqAxU2b9m6VckCVAqYAeMDGKEuZ5JmEQzYGVRSJzPn7iJ2E0AKAEFwcs1EGJagSyjE7n9PG9K53YTqbvjk_hFN21JhloLP9nbDXh_uX2TxZPD8-ze4Wic153ieKBMrKEje1IZVnpZJVxmvkWWFUKUE0pLIGUdYSK9sURUGiEpzAojG8kdmEXe96N777GCj0euWCpeXSrKkbguZYKoEq4xjRqz9o2w1-Hb_TnIMSca1UkcIdZX0XgqdGb7xbGf-lEfTWl2519KW3vjSgjr5i5nLfPFQrqn8TP4IicLsDKKr4dOR1sI7Wlmrnyfa67tw_9d94anej</recordid><startdate>201904</startdate><enddate>201904</enddate><creator>Pietschmann, Thomas</creator><creator>Brown, Richard J.P.</creator><general>Elsevier Ltd</general><general>Elsevier Science Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>201904</creationdate><title>Hepatitis C Virus</title><author>Pietschmann, Thomas ; Brown, Richard J.P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c424t-9e518bce2adae943798b32d1236a97805fe93f118d81bcf666e5b52e0c1aa2f83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Antiviral Agents - therapeutic use</topic><topic>antiviral therapy</topic><topic>Carcinoma, Hepatocellular - virology</topic><topic>HCV</topic><topic>Hepacivirus - drug effects</topic><topic>Hepacivirus - physiology</topic><topic>Hepatitis</topic><topic>Hepatitis C</topic><topic>Hepatitis C - drug therapy</topic><topic>Hepatitis C - immunology</topic><topic>Hepatitis C - prevention & control</topic><topic>Hepatitis C - virology</topic><topic>Humans</topic><topic>Immune Evasion</topic><topic>infection</topic><topic>liver disease</topic><topic>Serine Proteases</topic><topic>Viral Nonstructural Proteins</topic><topic>Viral Proteins - metabolism</topic><topic>Viral Vaccines</topic><topic>Virus Assembly</topic><topic>Virus Replication</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pietschmann, Thomas</creatorcontrib><creatorcontrib>Brown, Richard J.P.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Trends in microbiology (Regular ed.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pietschmann, Thomas</au><au>Brown, Richard J.P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hepatitis C Virus</atitle><jtitle>Trends in microbiology (Regular ed.)</jtitle><addtitle>Trends Microbiol</addtitle><date>2019-04</date><risdate>2019</risdate><volume>27</volume><issue>4</issue><spage>379</spage><epage>380</epage><pages>379-380</pages><issn>0966-842X</issn><eissn>1878-4380</eissn><abstract>[Display omitted]
Hepatitis C virus (HCV) is an enveloped, RNA virus transmitted through blood-to-blood contact. It infects humans only and primarily targets liver cells. HCV evades innate and adaptive immunity and establishes chronic infections in 70% of cases. If untreated, 20% of patients develop liver cirrhosis, and a fraction of these progress to hepatocellular carcinoma. Annually, 400000 patients die globally due to HCV infection. Direct-acting antivirals (DAAs) are licensed and target three viral proteins: the NS3-4A protease needed for processing the viral polyprotein, the NS5A phosphoprotein that regulates RNA replication and virus assembly, and the viral RNA-dependent RNA polymerase (NS5B) that catalyzes genome replication. Combination therapies cure more than 95% of treated patients. Approximately 71 million people are chronically infected and 1.7 million new infections occur annually. Treatment-induced cure does not protect from viral reinfection. A prophylactic vaccine is under development.
[Display omitted]</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>30709707</pmid><doi>10.1016/j.tim.2019.01.001</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0966-842X |
| ispartof | Trends in microbiology (Regular ed.), 2019-04, Vol.27 (4), p.379-380 |
| issn | 0966-842X 1878-4380 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2179519321 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Antiviral Agents - therapeutic use antiviral therapy Carcinoma, Hepatocellular - virology HCV Hepacivirus - drug effects Hepacivirus - physiology Hepatitis Hepatitis C Hepatitis C - drug therapy Hepatitis C - immunology Hepatitis C - prevention & control Hepatitis C - virology Humans Immune Evasion infection liver disease Serine Proteases Viral Nonstructural Proteins Viral Proteins - metabolism Viral Vaccines Virus Assembly Virus Replication Viruses |
| title | Hepatitis C Virus |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T04%3A28%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hepatitis%20C%20Virus&rft.jtitle=Trends%20in%20microbiology%20(Regular%20ed.)&rft.au=Pietschmann,%20Thomas&rft.date=2019-04&rft.volume=27&rft.issue=4&rft.spage=379&rft.epage=380&rft.pages=379-380&rft.issn=0966-842X&rft.eissn=1878-4380&rft_id=info:doi/10.1016/j.tim.2019.01.001&rft_dat=%3Cproquest_cross%3E2209580579%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2209580579&rft_id=info:pmid/30709707&rft_els_id=S0966842X19300137&rfr_iscdi=true |